As of mid-2026, trader consensus heavily favors no new pandemic this year, with the 90.5% implied probability for “No” reflecting official surveillance data from the WHO and CDC showing contained regional outbreaks rather than sustained global human-to-human transmission. Ebola Bundibugyo cases in the DRC and Uganda remain a public health emergency of international concern but exhibit limited spread via bodily fluids, while a hantavirus cluster tied to cruise travel has not escalated. COVID-19 transmission is declining across most U.S. states per reproductive number estimates, and avian influenza strains like H5N1 show no confirmed efficient human adaptation. Although zoonotic risks and unknown pathogens (Disease X) persist, enhanced post-2025 pandemic agreement surveillance and the inherent rarity of pandemics—typically requiring specific viral traits for airborne efficiency—support the strong market position. A sudden mutation enabling widespread respiratory transmission could still shift odds before year-end.